The Center for Breakthrough Medicines at Discovery Labs, an ecosystem accelerating the path to commercialization for cell and gene therapy companies, has appointed Matthew Snyder to the role of Associate Director, Engineering & Facilities. Mr. Snyder will be responsible for establishing the critical support services necessary for laboratory and manufacturing operations. These include setup of a comprehensive safety program; implementation of equipment tracking and maintenance and calibration management systems; interface coordination between site infrastructure utilities, building monitoring and process control systems; and technical engineering support for process operations and facility design.
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector.
Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs.
Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs.
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Byung Ha Lee, Ph.D., as Chief Scientific Officer (CSO) effective March 1st, 2021. Dr. Lee brings extensive scientific experience to the leadership team, with over 15 years of diverse drug development experience. In this new role, Dr. Lee will lead the effort to further demonstrate the scientific strength and maximize the scientific value of the Company’s products.
TEDCO, Maryland’s economic engine for technology companies, announced today the appointment of Jack Miner as the chief investment officer. He begins his tenure with TEDCO on March 1, 2021.
Arcellx, a privately-held clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced the appointment of Rami Elghandour as Chairman of the Board and Chief Executive Officer, effective Jan. 22, 2021. Arcellx’s founder and CEO, David Hilbert, Ph.D., will transition to the new role of Chief Technical Officer.
Ernesto P. Chanona, Ph.D. has joined CSSi LifeScience as Director of Business Development. His role will be to find opportunities by developing strategic partnerships with innovation hubs, incubators, entrepreneurs, government agencies, and academic researchers. Some of the company’s clients are overseas, so he will be contributing to the relationship management of their global government partners. Internally, he will be part of the marketing and operations teams, helping to shape the company’s message and helping to grow the business development department.
